Literature DB >> 12765222

Myofibroblasts proliferation of idiopathic and collagen vascular disorders associated nonspecific interstitial pneumonia.

Takashi Niimi1, Takeo Yoshinouchi, Yuji Ohtsuki, Jiro Fujita, Shigeki Sato, Yoshiki Sugiura, Kazutaka Ohta, Motoharu Kajiura, Ryuzo Ueda.   

Abstract

Nonspecific interstitial pneumonia (NSIP) has been recognized as a separate histological classification of interstitial lung disease. Similar features are found not only in idiopathic NSIP, but also in NSIP associated with collagen vascular disorder (CVD-NSIP). We examined the clinical symptoms, laboratory findings, and prognosis of 13 cases of idiopathic NSIP and 11 cases of CVD-NSIP. Immunohistochemical staining was performed using the streptavidin/biotin/peroxidase method with anti-alpha-smooth muscle actin antibody. No differences in the distribution of clinical features, laboratory findings, and prognosis were observed between idiopathic NSIP and CVD-NSIP. In immunohistochemical staining of the fibrosing areas, myofibroblasts were observed in 7 of 13 idiopathic NSIP cases, but in 10 of 11 CVD-NSIP cases. With regards to intra-alveolar organization, myofibroblasts were observed in all 10 CVD-NSIP cases, but they were observed in only 2 of 9 idiopathic NSIP cases. We found a significantly higher myofibroblast proliferation in the intra-alveolar organization of CVD-NSIP compared to idiopathic NSIP. Clinically, idiopathic NSIP and CVD-NSIP are similar, but are pathologically different.

Entities:  

Mesh:

Year:  2003        PMID: 12765222     DOI: 10.18926/AMO/32845

Source DB:  PubMed          Journal:  Acta Med Okayama        ISSN: 0386-300X            Impact factor:   0.892


  2 in total

1.  Effect of montelukast, a cysteinyl receptor antagonist, on myofibroblasts in interstitial lung disease.

Authors:  Elizabeth Fireman; Yehuda Schwartz; Abraham Mann; Joel Greif
Journal:  J Clin Immunol       Date:  2004-07       Impact factor: 8.317

Review 2.  Role of antifibrotics in the management of idiopathic inflammatory myopathy associated interstitial lung disease.

Authors:  Erin M Wilfong; Rohit Aggarwal
Journal:  Ther Adv Musculoskelet Dis       Date:  2021-12-09       Impact factor: 3.625

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.